Biopharmaceutical company GSK plc (LSE/NYSE:GSK) on Wednesday reported positive news regarding the ongoing Zantac (ranitidine) litigation.
The Delaware Supreme Court has agreed to review a lower court's decision allowing the introduction of plaintiffs' expert evidence. This is a significant development, as interlocutory reviews are granted in exceptional circumstances.
The company maintains that the scientific consensus remains clear: there is no consistent or reliable evidence linking ranitidine to an increased risk of cancer. Numerous epidemiological studies support this position, including data from over 1 million patients.
GSK said that it is committed to defending itself vigorously and managing this litigation in the best interests of the company and its shareholders. The Delaware litigation will proceed alongside the Supreme Court review, and GSK will continue to press additional defences, such as requiring plaintiffs to prove both ranitidine use and a diagnosis.
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Pheon Therapeutics names new independent, non-executive director
Solu Therapeutics names new chief medical officer
Carisma and Moderna expand collaboration
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024
Cantargia reports promising data for nadunolimab in cancer treatment
Hemogenyx Pharmaceuticals announces readiness of FLT3 assay for Phase I Trials at MD Anderson
Avacta announces presentation of updated data on AVA6000 at ESMO Congress 2024